



COVAX Facility update

Vaccine Procurement Practitioners Exchange Forum

Derrick Sim

Director, Vaccines Supply and Demand

15 December 2020

Our goals

To support the largest actively managed portfolio of vaccine candidates globally

To deliver 2 billion doses by end of 2021

To offer a compelling return on investment by delivering COVID-19 vaccines as quickly as possible

To guarantee fair and equitable access to COVID-19 vaccines for all participants

To end the acute phase of the pandemic by the end of 2021

Thanks to industry as a key partner in this endeavor



One world, protected.

Together we are stronger than we are apart

The logo for CEPI (Coalition for Epidemic Preparedness Innovations) consists of the letters 'C', 'E', 'P', and 'I' in a bold, sans-serif font. A small red dot is positioned above the letter 'E'.

Supporting vaccine research and development and manufacturing scale-up from the lab to the production facility



Pooling procurement and incentivizing manufacturing expansion to secure rapid supply of safe and efficacious vaccines



Providing normative guidance on vaccine policies, safety, regulation, and allocation

Objectives of COVAX


To end the acute phase of the pandemic by end 2021

To deliver 2 billion doses by end 2021

To guarantee fair and equitable access to COVID19 vaccines for all participants

To support the largest actively managed portfolio of vaccine candidates globally

To offer a compelling return on investment by delivering COVID19 vaccines as quickly as possible



The COVAX Facility

Developing a vaccine against COVID-19 is the most pressing challenge of our time – and nobody wins the race until everyone wins.

The COVAX Facility is the global mechanism to source COVID-19 vaccines for COVAX. The COVAX Facility will make investments across a broad portfolio of selected promising vaccine candidates.

By pooling purchasing power from all countries that participate, the COVAX Facility will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval.

Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries.

The COVAX Facility serves all participants

The COVAX AMC is an instrument for ODA-eligible countries

For all participants

The COVAX Facility

The AMC 92
ODA supported

For ODA-eligible participants

186 Participants representing over 85% of the world's population

Participant Engagement

	Number of participants	Total Population mn
Fully Self-Financing	94	3,048
AMC92	92	3'919
Total	186	6,967


Funding

> \$1 Billion
 received in upfront payments from Self Financing Participants

90%
 Pledges received for 2020 initial seed financing for AMC \$2 billion fundraising target

At least \$5billion additional is sought for 2021 AMC target plus delivery support

The COVAX Facility portfolio will include a broad range of candidates



COVAX Facility portfolio currently includes 3 candidates with several expected near-term agreements



COVAX Facility portfolio currently includes signed commitments with 3 candidates across 2 technology platforms



SII deal gives AMC92 economies access to vaccines licensed from Novavax and AstraZeneca

To date, the COVAX Facility has signed...

Deal with **SII** to provide doses for AMC92 economies
SII / AstraZeneca collaboration announced on Aug 7, 2020¹
SII / Novavax collaboration announced on Sep 29, 2020²

MoU with **AstraZeneca**
Announced on Jun 4, 2020³

Statement of Intent with **Sanofi / GSK**
Announced on October 28, 2020⁴

Several candidates are in near-term MoU agreements

1. [Gavi press release](#); 2. [Gavi press release](#); 3. [Gavi press release](#); 4. [Gavi press release](#)

Overview of COVID-19 vaccine landscape

42

candidates currently in human clinical trials

8

of the 9 candidates from CEPI R&D portfolio are in human clinical trials

10

candidates are currently in phase IIb/III and III

9 Nov 2020






date of 1st efficacy data readouts, which are needed to start process for emergency use authorizations (EUA) / emergency use licensure (EUL)
(subject to safety and efficacy data)

Q1/Q2 2021

expected dates for first EUA/EULs and start date for commercial distribution

COVID-19 Vx landscape (2/4) – 42 candidates in human clinical trials

● COVAX MoU or Sol signed¹ ● CEPI agreement signed² □ COVAX R&D candidate □ CEPI funded candidate for R&D outside COVAX R&D portfolio

Technology platform	Phase I				Phase I/II	Phase II	Phase IIb/III and III	
 Viral vectors	Shenzhen GIMI aAPC	Merck / Themis TMV-083	Vaxart VXA-CoV2-1	ImmunityBio / NantKwest nAd5-S-Fusion	Shenzhen GIMI LV-SMENP-DC		CanSino Ad5-nCoV	AstraZeneca ChAdOx1-S
	ReiThera GRAd-COV2	Wantai / Xiamen DelNS1	LMU Munich MVA-SARS-2-S				Gamaleya Gam-COVID-Vac	Janssen Ad26.COV2-S
 mRNA	Walvax Biotech ARCoV				Imperial LNP-nCoVsaRNA	CureVac CVnCoV	Pfizer / BioNTech BNT162	
					Arcturus ARCT-021		Moderna mRNA-1273	
 DNA					Genexine GX-19	Inovio INO-4800		
					Osaka / AnGes AG0301 / AG0302	Zydus Cadila ZyCoV-D		
 Protein-based	Medicago / GSK VLP	West China Hospital / U. of Sichuan	Vaxine / Medytox COVAX-19	Medigen MVC-COV1901	FBRI SRC EpiVacCorona	SpyBiotech RBD-HBsAg VLP	Anhui Zhifei RBD-Dimer	Novavax NVX-CoV2373
	CSL / Queensland	Covaxx UB-612	Clover SCB-2019		Finlay FINLAY-FR-1	Sanofi / GSK recombinant		
 Inactivated	Shenzhen Kangtai				Bharat Biotech COVAXIN	Inst. of Medical Biology / CAMS	Sinopharm / WIBP	Sinovac / Butantan CoronaVac
					RIBSP QAZCOVID-IN		Sinopharm / BIBP BBIBP-CorV	

1. For advanced purchase agreement (APA); 2. For tech transfer, scale-out and reservation fees

Source: CEPI Vx landscape

CEPI R&D portfolio – 9 pipeline assets, 8 in human in clinical trials

	DNA / mRNA			Viral vectors			Protein-based		
Candidate	Inovio INO-4800	Moderna mRNA-1273	CureVac CVnCoV	Merck / Themis V591	AstraZeneca ChAdOx1-S	U. of Hong Kong	Novavax NVX-CoV2373	Clover SCB-2019	CSL / Queensland
Location	USA	USA	Germany	USA / Austria	UK	China	USA	China	Australia
Antigen / adjuvant	Full-length S protein	Full-length S protein	Full-length S protein	Full-length S protein	Full-length S protein	Receptor Binding Domain / AS03	Full-length S protein / saponin-based Matrix-M	Full-length S protein/AS03 or CPG1018	Full-length S protein / MF59 or AS03 or CPG1018
Current phase	Phase I/II	Phase III	Phase II	Phase I	Phase III	Pre-clinical	Phase III	Phase I	Phase I



Speed



Scale




Access

Candidates to be included in the COVAX Facility portfolio are being selected from the CEPI R&D portfolio and other clinical candidates

ILLUSTRATIVE


CEPI R&D portfolio

CEPI invests in R&D for selected promising candidates to accelerate vaccine availability




COVID-19 Vx pipeline candidates

All candidates¹ in the COVID-19 vaccine landscape in clinical development stages



Selection process



COVAX Facility portfolio

Selected candidates from the COVAX R&D portfolio and other clinical candidates from the Vx landscape



COVAX portfolio will include selected promising candidates across different technologies and geographies

1. Excluding those in CEPI R&D Portfolio

Additional candidates will be brought into the COVAX Facility portfolio through newly established processes




(A) UNICEF / PAHO joint RfP

The RfP will support the establishment of APAs and supply arrangements for purchase and delivery. All manufacturers that are expecting to have supply available by end-2021 are invited to respond to the RfP


(B) Independent Product Group (IPG)

IPG will assess suitable candidates and make recommendations on inclusion in the COVAX Facility portfolio

COVAX Facility portfolio candidates are selected based on several criteria



Final COVAX Facility portfolio is expected to have around 10 or more candidates across 4-5 technology platforms, with early doses available in Q1 2021



COVAX Facility portfolio

The COVAX Facility aims for a diverse and actively managed portfolio of around 10 or more vaccine candidates to achieve 2 billion doses by the end of 2021

- Diversifying technologies
- Diversifying geographies
- Diversifying vaccine characteristics
- Accounting for attrition

Thank you



COVAX

#ONEWORLDPROTECTED